Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
RT-102, RaniPill capsule containing proprietary formulation of human PTH analog PTH (1-34) for potential treatment of osteoporosis achieved all of its endpoints, with RT-102 being generally well-tolerated and demonstrating high oral bioavailability of Rani’s PTH analog.
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Product Name: RT-102
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
Details:
The financing agreement is expected to support the continued advancement of the RaniPill platform and ongoing clinical development of the Company’s drug pipeline including RT-102.
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Product Name: RT-102
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Avenue Venture Opportunities Fund
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 08, 2022
Details:
SPI-47 (SPI-62) prevented several CORT adverse effects, demonstrating that by blocking local intracellular glucocorticoid activation with a HSD-1 inhibitor in target tissues, it can mitigate glucocorticoid toxicity.
Lead Product(s): SPI-62,Prednisolone
Therapeutic Area: Musculoskeletal Product Name: SPI-47
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2022
Details:
Phase 1 clinical trial data showed that SP-104 (naltrexone hydrochloride) treated healthy volunteers and had lower rates of adverse events, as compared with immediate release naltrexone -treated volunteers.
Lead Product(s): Naltrexone Hydrochloride
Therapeutic Area: Musculoskeletal Product Name: SP-104
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2022
Details:
TST002 (Blosozumab) is a humanized anti-sclerostin mAB for osteoporosis has a dual effect possessing both anabolic and anti-resorptive effects, which stimulates bone formation and inhibits bone absorption, resulting in fast increase in bone mineral density and bone strength.
Lead Product(s): Blosozumab
Therapeutic Area: Musculoskeletal Product Name: TST002
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
In aged mouse models, a highly selective and potent small-molecule agonist of the apelin receptor APJ, BGE-105 substantially rescued muscle atrophy due to limb immobilization, prevented loss of muscle function with age, and induced biomarkers of muscle regeneration.
Lead Product(s): BGE-105
Therapeutic Area: Musculoskeletal Product Name: BGE-105
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
In preclinical studies, RT-102, an oral formulation of the human parathyroid hormone delivered via RaniPill™ capsule demonstrated a pharmacokinetic profile comparable to published data of PTH(1-34) injections for the treatment of osteoporosis.
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Product Name: RT-102
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2022
Details:
Oncocross obtained Australia’s TGA approval on phase I IND application for OC514, aims to evaluate the safety, pharmacokinetics, and pharmacodynamics for targeting muscular diseases including sarcopenia.
Lead Product(s): OC514
Therapeutic Area: Musculoskeletal Product Name: OC514
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2022
Details:
Company oral formulation of psilocybin (TRP-8802), in combination with psychotherapy in subjects with overeating disorders including but not limited to hypothalamic obesity, binge-eating disorder, and Prader-Willi Syndrome, expects to initiate the Phase 2a study in 2022.
Lead Product(s): Psilocybine
Therapeutic Area: Musculoskeletal Product Name: TRP-8802
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2021
Details:
EB-CLIN-1001-03 phase 3 clinical trial for the leading biosimilar program EB1001, a Denosumab biosimilar, for the future treatment of osteoporosis, giant cell tumors of bone, and other skeletal-related events from metastatic solid tumors.
Lead Product(s): Denosumab
Therapeutic Area: Musculoskeletal Product Name: EB1001
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2021
